ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022: Post-Remission Outcomes in Patients With AML Are Similar Between HMA/Venetoclax Therapy & Intensive Chemo After Accounting for MRD Status
By
ASH 2022 Conference Coverage
FEATURING
Michael Hochman
By
ASH 2022 Conference Coverage
FEATURING
Michael Hochman
174 views
December 28, 2022
Login to view comments.
Click here to Login
Leukemia